PharmaTher Advances Strategy to Build Next-Generation Ketamine Franchise for Neuropsychiatric Disorders; Secures Exclusive Rights to Evaluate and License Patent…

PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company ...

PharmaTher Holdings Ltd.: PharmaTher Advances Strategy to Build Next-Generation Ketamine Franchise for Neuropsychiatric Disorders; Secures Exclusive Rights to Evaluate and ...

PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking the ...
TipRanks on MSN

PharmaTher Secures Rights to Long-Acting Ketamine Program for Neuropsychiatric Disorders

The latest announcement is out from PharmaTher Holdings Ltd ( ($TSE:PHRM) ). PharmaTher Holdings Ltd. has entered into an exclusive agreement with ...
TipRanks on MSN

NRx Pharmaceuticals (NASDAQ: NRXP) Advancing Two-Pronged Approach to Bring Innovative Therapies to Market

Austin, Texas, United States, October 27th, 2025, FinanceWire NRx Pharmaceuticals (NASDAQ: NRXP) was featured in a recent article that ...
Benzinga.com

NRx Pharmaceuticals (NASDAQ: NRXP) Advancing Two-Pronged Approach to Bring Innovative Therapies to Market

NRx Pharmaceuticals (NASDAQ: NRXP) was featured in a recent article that discussed its approach to bring preservative-free ketamine-based therapies to market, pursuing distinct regulatory and ...
Mena FN

Investornewsbreaks Nrx Pharmaceuticals Inc. (NASDAQ: NRXP) Advancing Two-Pronged Approach To Bring Innovative Therapies To Market

(MENAFN- Investor Brand Network) NRx Pharmaceuticals (NASDAQ: NRXP) was featured in a recent article that discussed its approach to bring preservative-free ketamine-based therapies to market, pursuing ...
Itemlive

Safe, Supervised, and Grounded in Care: How Lumin Health Delivers Ketamine Therapy Responsibly

Ketamine therapy can be remarkably effective for people with treatment-resistant depression.  That said, many people have first heard about ketamine in the context of its use as an anesthetic agent or ...
PharmExec

Winners & Losers: What the First FDA Commissioner’s National Priority Vouchers Tell Us About Early Movers vs. Late Movers

The first wave of Commissioner’s National Priority Vouchers signals a fundamental shift in FDA competitiveness, rewarding companies that pair breakthrough science with affordability commitments, ...

NRx Pharmaceuticals, Inc. (NRXP) Q3 2025 Earnings Call Transcript

Q3 2025 Earnings Call November 17, 2025 8:30 AM ESTCompany ParticipantsMatthew Duffy - Chief Business Officer & ...
PharmiWeb

MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication

This milestone follows the completion of dosing in the single ascending dose (SAD) portion of the study. According to data reviewed to date, no serious or dose-limiting adverse events have been ...
News-Medical.Net on MSN

The caffeine conundrum in rapid depression treatments

Perhaps the most intriguing implication of recent breakthrough research lies in an unexpected connection: the most rigorous mechanistic dissection of rapid antidepressant action identifies adenosine ...
EurekAlert!

Adenosine is the metabolic common pathway of rapid antidepressant action: The coffee paradox

A commentary published in Brain Medicine by Drs. Julio Licinio and Ma-Li Wong examines groundbreaking research identifying adenosine signaling as the convergent mechanism underlying rapid-acting ...